Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024 · DOI: https://doi.org/10.1631/jzus.B2300790 · Published: September 25, 2024
This study explores the potential of stem cells from bone marrow in the skull (cBMMSCs), especially a purified type called Olig2+ sc-cBMMSCs, to help repair damage in a mouse model of a disease similar to multiple sclerosis (MS). MS involves the loss of myelin, which protects nerve fibers. The researchers used a chemical called cuprizone to cause myelin damage in the mice, mimicking MS. Then, they transplanted either regular cBMMSCs or the purified Olig2+ sc-cBMMSCs into the mice to see if they could improve the animals' condition. The results showed that both types of stem cells helped the mice recover some motor and cognitive functions. However, the purified Olig2+ sc-cBMMSCs seemed to work even better, suggesting that selecting specific types of stem cells could improve treatment for demyelinating diseases like MS.
The study suggests that cBMMSCs, particularly Olig2+ sc-cBMMSCs, hold promise as a therapeutic strategy for demyelinating diseases like multiple sclerosis.
Enriching stem cell populations with specific subtypes, such as Olig2+ cells, can enhance the therapeutic efficacy of stem-cell-based therapies.
The immunomodulatory effects of MSCs, including the reduction of pro-inflammatory cytokines, may contribute to tissue repair and a more favorable environment in demyelinating conditions.